Oh ST, et al. - Researchers examined how the drug (donepezil, rivastigmine, galantamine, and memantine) compliance influence the healthcare costs in newly-diagnosed dementia. Using National Health Insurance Service database, which covers the entire population of South Korea, they examined 252,594 patients newly-diagnosed with dementia for their healthcare expenditure between 2012 and 2014 for 3–5 years. Using Medication Possession Ratio (MPR) that indicates the percentage of time a patient has access to medication, they assessed drug compliance. Findings revealed a decrease in total healthcare costs by 8.4% when an increase in initial MPR by 20% occurred. They noted the same relationship with medical costs related to dementia, admission to a general hospital, and emergency room visits. They observed a decrease in the total healthcare costs, admission to a general hospital, emergency room visits, and admission to a nursing hospital when an increase in MPR by 20% compared to the previous year occurred. Findings thereby support the possibility for the incurrence of benefit in total healthcare costs by patients newly-diagnosed with dementia who showed higher initial drug compliance or maintained antidementia drugs (Cholinesterase inhibitors and memantine).